Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
about
Safety of dipeptidyl peptidase 4 inhibitors: a perspective reviewDiabetic kidney disease: a report from an ADA Consensus ConferenceTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsPositive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse ElectrophilesPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: a meta-analysis of clinical trials.Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in swedenObservational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement.Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SCombined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.Management of Hyperglycemia in Diabetic Kidney Disease.Hypoglycemia, diabetes, and cardiovascular disease.Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agentEffects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study.Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.Metformin: an old but still the best treatment for type 2 diabetes.Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion.Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.Advances in pharmacologic therapies for type 2 diabetes.Dysglycaemia in the critically ill - significance and management.Glucagon-like peptide-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity.Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.Brown adipose tissue thermogenesis in the resistance to and reversal of obesity: A potential new mechanism contributing to the metabolic benefits of proglucagon-derived peptides.Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia.Understanding incretins.Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.
P2860
Q26863262-CF44D9D0-934D-40B0-BBCA-96A0C8A95360Q27012546-EB550CDE-AFC7-4CF8-95DB-5C160206451AQ28077026-6A177601-28C6-4497-9E02-DBF2504A678AQ28294225-D31086E6-B0BD-4D7A-89D3-983F383F8743Q28834277-875E591A-5324-4B1D-B0A8-35F66210A14EQ30249371-21677D61-80CB-40CB-8C7F-F2596E90ADA1Q34081331-4EADF16E-7B77-4079-8FCC-165C10D5C248Q34368524-7487DC6B-F0D3-4934-AF29-011238C68EE6Q34659086-3720CF25-18B6-493C-88EF-24728E0B6636Q34726534-60E556D1-72EA-40F3-ABC7-F47E954AB0D3Q35146648-F4419153-0412-4E97-81BA-BBC27F1763A9Q35192193-FA47603A-454F-48BC-B388-5571DDF9532EQ35800392-EC8E16B1-2C57-4D80-8317-9F80F62999A2Q35953856-86417BB7-B104-403E-AA17-48EEA7352C95Q35990856-537EED4C-0AA2-4E56-A10E-11F7F59406CFQ36192977-A4FF10DE-F6A2-4A70-AADC-D4E022AD5222Q36209444-93CE8BE9-0680-40C5-AFAB-EE53B97E721DQ36365237-8819CEC8-9375-4D61-9CCF-12AC063F8B1AQ36376273-1B6968F2-9C60-4F8E-8526-193484B671F8Q36715464-DED38427-E44F-4DF2-BBB8-96E40081B479Q36924521-DFC0FA2C-51EE-435D-9D1D-CF4EC0E56383Q36989711-E24856B3-A978-4571-B848-C2F2D374DC5DQ37324757-7E0F067D-5A13-4012-B3A1-CBC708C5635DQ37402786-12FA8720-BD69-41D8-885A-453E13F58C9DQ37427294-CD32EA59-2E5D-4A43-BBE8-964864E1CCFBQ37510200-5B75C0CE-08F2-4EBC-98D8-FAF5614FD922Q37598881-8C433FB0-5063-4D12-9A3F-7AB5A2DAFCCCQ37653125-BCEB2338-9F6B-4FB2-8D86-A6F433D0C92DQ37737463-48880CCF-45CE-47EA-A64F-A93A1F30217CQ38072616-221E8C56-F24A-4CE9-850A-4FC135F8B745Q38078016-93C2287A-01B0-41B1-997F-855DD02A5CA4Q38099388-1DC1CCD3-DBEE-4D15-80A3-9D35FD65D277Q38106411-2EF7D427-B2F4-4E5F-B64B-694D95F7202EQ38126945-33ED0616-0A7F-4380-9919-E5F531A79E68Q38139935-3952D6BC-8567-4B4D-BFE2-1B39AD3883D5Q38198185-15ED7AA1-B406-40EA-BAF3-57549DE7B2E7Q38212472-B2644EB0-4B1F-4BD6-9D64-DAFCB7D2BD51Q38234927-73C8F87F-D606-4A77-9ACB-32DDC89F5464Q38241343-280066AF-71C5-4A02-A5D7-3DF13C51789CQ38242089-6F97525A-EEC9-4906-9202-5827B744CCC7
P2860
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Glycaemic efficacy of glucagon ...... es-a review and meta analysis.
@ast
Glycaemic efficacy of glucagon ...... es-a review and meta analysis.
@en
Glycaemic efficacy of glucagon ...... es-a review and meta analysis.
@nl
type
label
Glycaemic efficacy of glucagon ...... es-a review and meta analysis.
@ast
Glycaemic efficacy of glucagon ...... es-a review and meta analysis.
@en
Glycaemic efficacy of glucagon ...... es-a review and meta analysis.
@nl
prefLabel
Glycaemic efficacy of glucagon ...... es-a review and meta analysis.
@ast
Glycaemic efficacy of glucagon ...... es-a review and meta analysis.
@en
Glycaemic efficacy of glucagon ...... es-a review and meta analysis.
@nl
P2860
P921
P1476
Glycaemic efficacy of glucagon ...... es-a review and meta analysis.
@en
P2093
C F Deacon
E Mannucci
P2860
P304
P356
10.1111/J.1463-1326.2012.01603.X
P50
P577
2012-04-24T00:00:00Z